We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 27.50 | 1.59% | 1,761.00 | 1,757.50 | 1,758.00 | 1,767.00 | 1,736.00 | 1,736.00 | 14,302,622 | 16:35:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.69 | 72.38B |
From May 2019 to May 2024
By Matteo Castia
GlaxoSmithKline PLC said Monday that it will invest $250 million in Vir Biotechnology Inc. as part of their new partnership to research and develop solutions for the treatment of coronaviruses, including the one that causes Covid-19.
The British pharma group said the collaboration will use Vir's proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used to treat coronaviruses, while GlaxoSmithKline will provide expertise in functional genomics.
GlaxoSmithKline said that to gain access to Vir's technology, it will buy Vir's shares at $37.73, a 10% premium to the closing share price on Friday.
GlaxoSmithKline shares at 1315 GMT were up 3.2 pence, or 0.2%, at 1,492.6 pence.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
April 06, 2020 08:34 ET (12:34 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
